An Open-label Phase I Study of Orally Available Novel Small-molecule Fibroblast Growth Factor Receptors (FGFR) 1,2,3 and 4 Inhibitor, ASP5878 at Single and Multiple Doses in Patients With Solid Tumors

Site US401, New York

Site US410, Fairfax

Site US406, Spartanburg

Site US404, Cleveland

Site US402, Orange

Site US403, Seattle

Site JP122, Chiba

Site JP108, Fukuoka

Site JP115, Fukuoka

Site JP120, Fukuoka

Site JP116, Hokkaido

Site JP113, Hyōgo

Site JP103, Ibaraki

Site JP111, Ishikawa

Site JP119, Kanagawa

Site JP101, Kyoto

Site JP109, Miyagi

Site JP110, Miyagi

Site JP112, Nagoya

Site JP117, Niigata

Site JP121, Okayama

Site JP104, Osaka

Site JP106, Osaka

Site JP118, Osaka

Site JP124, Shizuoka

Site JP102, Tokyo

Site JP107, Tokyo

Site JP123, Tokyo

Site KR202, Gyeonggi-do

Site KR201, Seoul

Site KR203, Seoul

Site KR204, Seoul

Site TW302, Tainan City

Site TW301, Taipei

Site TW303, Taipei